Literature DB >> 2442554

Renal effects of converting enzyme inhibition.

H R Brunner, B Waeber, J Nussberger.   

Abstract

Angiotensin-converting enzyme inhibition, by preventing the generation of angiotensin II, has some pronounced effects on renal function. Its actions occur at the vascular, the glomerular, the juxtaglomerular, and also at the tubular medullary level. In clinical medicine, depending on the circumstances of the patients under treatment, converting enzyme inhibitors can interfere with renal hemodynamics and glomerular filtration, with solute excretion by the kidney and other variables of normal renal function. In most circumstances, the effects of converting enzyme inhibition on the kidney are rather beneficial to the patient. However, under some extreme conditions, they may become potentially hazardous. A basic understanding of the physiology of the renin-angiotensin system and of its actions on the kidney makes it possible to understand the impact of the converting enzyme inhibitors, to avoid most of the unwanted effects and to ensure greatest benefit to the patient.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2442554     DOI: 10.1097/00005344-198700003-00003

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  A comparative study of lisinopril and atenolol on low degree urinary albumin excretion, renal function and haemodynamics in uncomplicated, primary hypertension.

Authors:  O Samuelsson; T Hedner; S Ljungman; H Herlitz; B Widgren; K Pennert
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Acute and chronic effects of lisinopril on renal and systemic hemodynamics in hypertension.

Authors:  J P Degaute; M Leeman; C Reuse; E Carlier; A Schoutens; P Vandepapeliere
Journal:  Cardiovasc Drugs Ther       Date:  1992-10       Impact factor: 3.727

3.  Lisinopril reduces postexercise albuminuria more effectively than atenolol in primary hypertension.

Authors:  C Rangemark; H Lind; L Lindholm; T Hedner; O Samuelsson
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 4.  Clinical relevance of drug interactions with lithium.

Authors:  P R Finley; M D Warner; C A Peabody
Journal:  Clin Pharmacokinet       Date:  1995-09       Impact factor: 6.447

5.  Ramipril-induced decrease in renal lithium excretion in the rat.

Authors:  M Barthelmebs; M Grima; J L Imbs
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

Review 6.  Adverse effects of angiotensin converting enzyme (ACE) inhibitors. An update.

Authors:  R C Parish; L J Miller
Journal:  Drug Saf       Date:  1992 Jan-Feb       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.